{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:53:49Z","timestamp":1790970829183,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,2]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study evaluated the association of prolonged fenofibrate therapy with recurrent hypertriglyceridemic pancreatitis (HTGP), long-term triglyceride control, and safety during follow-up. This single-center retrospective cohort study included consecutive patients with HTGP diagnosed between January 2023 and December 2024. Patients who survived the index hospitalization and had post-discharge follow-up data were classified into a prolonged fenofibrate group or a control group according to treatment status. Prolonged fenofibrate therapy was defined as documented continuous use for at least 3 months after discharge. The primary outcome was recurrent HTGP. Secondary outcomes included time to 1st recurrence, descriptive crude recurrence proportions at 6, 12, and 24 months, pancreatitis-related readmission, recurrent hospital stay, follow-up triglyceride (TG) control, and safety outcomes. A total of 200 patients were included, including 107 in the prolonged fenofibrate group and 93 controls. Recurrent HTGP occurred in 17 patients (15.9%) in the fenofibrate group and 24 (25.8%) in the control group. Recurrence was numerically lower with fenofibrate, but the crude comparison was not statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.081). Kaplan\u2013Meier analysis showed a similar numerical trend toward better recurrence-free survival (log-rank\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.067). In multivariable Cox regression, prolonged fenofibrate therapy showed a potential association with lower recurrence risk, but the estimate was not statistically significant (adjusted hazard ratio 0.58, 95% confidence interval 0.31\u20131.07,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.082). Previous HTGP remained independently associated with recurrence (adjusted hazard ratio 1.96, 95% confidence interval 1.06\u20133.63,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.032). Follow-up TG levels were lower in the fenofibrate group (3.9 [2.5\u20136.2] vs 5.1 [3.0\u20138.4] mmol\/L,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.012), and more patients achieved TG\u2005&lt;\u20055.6 mmol\/L (69.2% vs 53.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.026). Safety outcomes were comparable between groups. Prolonged fenofibrate therapy after HTGP was associated with improved long-term triglyceride control and an acceptable safety profile. Recurrence-related outcomes consistently favored fenofibrate numerically, but none reached statistical significance. Larger prospective multicenter studies are needed to clarify any effect on recurrence.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050647","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:01:48Z","timestamp":1790967708000},"page":"e50647","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of prolonged fenofibrate therapy after the acute phase of hypertriglyceridemic pancreatitis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8944-600X","authenticated-orcid":false,"given":"Luqiu","family":"Zeng","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Weiyuan County People\u2019s Hospital, Neijiang, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Gourong City Fourth People\u2019s Hospital, Zigong, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shen","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Weiyuan County People\u2019s Hospital, Neijiang, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261002","doi-asserted-by":"crossref","first-page":"419","DOI":"10.14309\/ajg.0000000000002645","article-title":"American college of gastroenterology guidelines: management of acute pancreatitis.","volume":"119","author":"Tenner","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"R2-20261002","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12328-018-0881-1","article-title":"Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies.","volume":"11","author":"Rawla","year":"2018","journal-title":"Clin J Gastroenterol"},{"key":"R3-20261002","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.pan.2020.06.005","article-title":"Hypertriglyceridemia and acute pancreatitis.","volume":"20","author":"Yang","year":"2020","journal-title":"Pancreatology"},{"key":"R4-20261002","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejim.2024.03.022","article-title":"Recurrence of hypertriglyceridemia-associated acute pancreatitis: a multicenter, prospective cohort study.","volume":"125","author":"Ding","year":"2024","journal-title":"Eur J Intern Med"},{"key":"R5-20261002","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11883-021-00962-z","article-title":"Clinical management of hypertriglyceridemia in the prevention of cardiovascular disease and pancreatitis.","volume":"23","author":"Hernandez","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"R6-20261002","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee.","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R7-20261002","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/diseases11040140","article-title":"Effectiveness and safety of fenofibrate in routine treatment of patients with hypertriglyceridemia and metabolic syndrome.","volume":"11","author":"Ezhov","year":"2023","journal-title":"Diseases"},{"key":"R8-20261002","doi-asserted-by":"crossref","first-page":"849","DOI":"10.46747\/cfp.6912849","article-title":"Reducing pancreatitis risk in patients with hypertriglyceridemia.","volume":"69","author":"MacDonald","year":"2023","journal-title":"Can Fam Physician"},{"key":"R9-20261002","doi-asserted-by":"crossref","first-page":"106648","DOI":"10.1016\/j.ejim.2025.106648","article-title":"Prevention and treatment of hypertriglyceridemia-mediated acute pancreatitis: a narrative review.","volume":"145","author":"Subramanian","year":"2026","journal-title":"Eur J Intern Med"},{"key":"R10-20261002","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12876-025-03954-4","article-title":"A systematic review of the epidemiology and risk factors for severity and recurrence of hypertriglyceridemia-induced acute pancreatitis.","volume":"25","author":"Lu","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"R11-20261002","first-page":"47","article-title":"Recurrence rates and risk factors for recurrence after first episode of acute pancreatitis: a systematic review and meta-analysis.","volume":"114","author":"Li","year":"2023","journal-title":"Eur J Intern Med"},{"key":"R12-20261002","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/JP9.0000000000000153","article-title":"Hypertriglyceridemia and acute pancreatitis: clinical and basic research \u2013 a narrative review.","volume":"7","author":"Gao","year":"2023","journal-title":"J Pancreatol"},{"key":"R13-20261002","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s12916-024-03755-8","article-title":"Triglyceride-lowering therapies in hypertriglyceridemia-associated acute pancreatitis in China: a multicentre prospective cohort study.","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med"},{"key":"R14-20261002","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/clinchem\/hvad094","article-title":"Hypertriglyceridemia-associated pancreatitis: new concepts and potential mechanisms.","volume":"69","author":"Hansen","year":"2023","journal-title":"Clin Chem"},{"key":"R15-20261002","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2022.11.006","article-title":"Recurrence for patients with first episode of hypertriglyceridemia-induced acute pancreatitis: a prospective cohort study.","volume":"17","author":"Ding","year":"2023","journal-title":"J Clin Lipidol"},{"key":"R16-20261002","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jacl.2022.08.001","article-title":"GPIHBP1 autoantibody is an independent risk factor for the recurrence of hypertriglyceridemia-induced acute pancreatitis.","volume":"16","author":"Zhang","year":"2022","journal-title":"J Clin Lipidol"},{"key":"R17-20261002","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s10620-018-5226-x","article-title":"Influence of ambulatory triglyceride levels on risk of recurrence in patients with hypertriglyceridemic pancreatitis.","volume":"64","author":"Wu","year":"2019","journal-title":"Dig Dis Sci"},{"key":"R18-20261002","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MPA.0000000000001235","article-title":"Severe hypertriglyceridemia-related pancreatitis: characteristics and predictors of recurrence.","volume":"48","author":"Zafrir","year":"2019","journal-title":"Pancreas"},{"key":"R19-20261002","doi-asserted-by":"crossref","first-page":"1079637","DOI":"10.3389\/fmed.2023.1079637","article-title":"Serum triglyceride levels are associated with recurrence in patients with acute hypertriglyceridemic pancreatitis.","volume":"10","author":"Guan","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R20-20261002","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cgh.2020.08.016","article-title":"Genetic variants associated with increased plasma levels of triglycerides, via effects on the lipoprotein lipase pathway, increase risk of acute pancreatitis.","volume":"19","author":"Hansen","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R21-20261002","doi-asserted-by":"crossref","first-page":"m3109","DOI":"10.1136\/bmj.m3109","article-title":"Management of hypertriglyceridemia.","volume":"371","author":"Simha","year":"2020","journal-title":"BMJ"},{"key":"R22-20261002","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/diagnostics14111105","article-title":"Hypertriglyceridemia-induced acute pancreatitis \u2013 the current state of knowledge.","volume":"14","author":"Edu","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"R23-20261002","first-page":"109","article-title":"Efficacy and adverse effects of insulin versus plasmapheresis in patients with hypertriglyceridemia-3-induced acute pancreatitis: a systematic review and meta-analysis.","volume":"37","author":"Piplani","year":"2024","journal-title":"Ann Gastroenterol"},{"key":"R24-20261002","doi-asserted-by":"crossref","first-page":"e17443","DOI":"10.1016\/j.heliyon.2023.e17443","article-title":"Lipid metabolism for predicting the recurrence of hypertriglyceridemic acute pancreatitis.","volume":"9","author":"Tang","year":"2023","journal-title":"Heliyon"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:01:51Z","timestamp":1790967711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050647"}},"subtitle":["A long-term retrospective follow-up study"],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":24,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050647","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"2026-04-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}